[
| E-mail
]
Contact: Ronald Rogersrrogers@myriad.com
801-584-3065Myriad Genetics, Inc.@myriadgenetics
Tumor BRACAnalysis CDx identifies 44 percent more candidates for PARP therapy
SALT LAKE CITY, Utah, Sept. 29, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that its Tumor…
Myriad presents tumor BRACAnalysis CDx study at ESMO
No comments:
Post a Comment